Objective: To find the survival and the predictors of death of HIV-infected patients with hepatitis C virus (HCV)-related end-stage liver disease (ESLD).
Introduction
Hepatitis C virus (HCV)-related liver disease follows an accelerated course in the setting of HIV co-infection. Liver fibrosis progression to cirrhosis is faster in HIV/ HCV-co-infected individuals than in HCV-monoinfected subjects [1] [2] [3] . Furthermore, HIV accelerates the evolution to decompensated HCV-related cirrhosis and death [4, 5] . Thus, a recent retrospective study has shown that the survival of HIV-infected patients harbouring HCV-related end-stage liver disease (ESLD) is shorter than that observed in HCV-monoinfected patients at the same stage of liver disease [6] .
The factors that contribute to this ominous evolution of liver disease in the HIV/HCV-co-infected population are not known. Specific circumstances of the HIV-coinfected patient, such as HIV-associated immunosuppression or the effect of specific antiretroviral drugs could explain these differences. In this sense, some hepatotoxic antiretroviral drugs frequently given to HIV/HCV-coinfected subjects might adversely affect the course of HCV-related liver cirrhosis in patients with advanced liver disease. By contrast, recent data have suggested that highly active antiretroviral therapy (HAART) could reduce the liver-related mortality in HIV/HCV-coinfected individuals [7, 8] . However, it is not known whether HAART also yields such a benefit in patients with ESLD. Furthermore, ESLD might represent a different scenario in which factors other than immunodeficiency and antiretroviral therapy (ART) influence the final outcome of the disease. This could be the case of markers of severe liver disease, specific hepatic decompensations, management of liver complications or continued alcohol intake. Given that liver transplantation is being considered as a suitable procedure for HIVinfected patients with HCV-related ESLD [9, 10] , it is relevant to know accurately the survival and the variables which are related with mortality in this population.
For these reasons, we undertook this study, whose objectives were to investigate the survival and the risk factors for death in HIV/HCV-co-infected patients with decompensated cirrhosis.
Methods
Study design and patients From January 1997 to June 2004 a multicentric cohort of 4524 HIV-infected patients has been prospectively followed in the Units of Infectious Diseases of four hospitals in Andalucía (Spain). A total of 2664 (59%) of them showed HCV co-infection. From this cohort, HIV/ HCV-infected patients who presented with decompensated liver cirrhosis at each participating hospital during the study period were included in this study if they met the following criteria: (1) older than 18 years; (2) no evidence of metabolic or autoimmune liver disease; (3) positive serum anti-HCV and detectable plasma HCV-RNA; and (4) no previous decompensation of liver disease.
Follow-up
All individuals received similar care in the four participating hospitals throughout the follow-up. All were evaluated at least every 3 months, including assessment of symptoms and signs of HIV disease or hepatic decompensation and haematological, immunological, virological and routine biochemical examinations. The guidelines of the Spanish Association for the Study of the Liver (www.aeeh.org) were used for liver disease management.
Prior to and after the first hepatic decompensation all patients were offered HAART if they were candidates according to the recommendations of international guidelines. Combinations of antiretroviral drugs included at least three drugs, one of which had to be abacavir, a protease inhibitor (PI) or a non-nucleoside reversetranscriptase inhibitor (NNRTI).
Diagnostic criteria
The diagnosis of cirrhosis was based on histological examination or on the combination of clinical, laboratory and imaging data supporting such a diagnosis. Cirrhosis was classified as decompensated in patients who presented with ascites, portal hypertensive gastrointestinal bleeding (PHGB), hepatic encephalopathy (HE), non-obstructive jaundice, spontaneous bacterial peritonitis (SBP) and hepatocellular carcinoma (HCC). The criteria used for the diagnosis of these events have been described elsewhere [6] . In the cases presenting with more than one simultaneous complication the event that led the patient to the hospital or the one that dominated the clinical picture in the opinion of the attending physician was considered as the first hepatic decompensation. The model for end stage liver disease (MELD) score at the time of first hepatic decompensation was calculated using the following equation: 3.78 ln(bilirubin) þ 9.57 ln(creatinine) þ 11.2 ln(INR) þ 6.4, where INR is the International Normalized Ratio [11] .
Life status and mortality causes Patients were prospectively seen until death or the censoring date (30 June 2004). The vital status and the causes of death were recorded. Subjects or their next of kin were contacted by telephone, if they were lost to follow-up. The regional death registry was used to establish the vital status and the date and cause of death in the cases definitely lost to follow-up. Survival times were calculated from the date of the first hepatic decompensation to the date of death or when the last information of life status was obtained, and it is expressed as median. Survival was analysed by the Kaplan-Meier method. Comparisons between groups were made by the log-rank test. Survival estimates at different time points of the follow-up were obtained using life tables. Cox's regression analysis was used to identify factors independently associated with liverrelated mortality. The variables included in these analyses were age, sex, daily alcohol intake, active intravenous drug use, the route and length of HCV infection, plasma HCV viral load, HCV genotype, prior therapy against HCV, alanine aminotransferase levels, Child-Pugh and MELD scores, hepatitis B and D virus co-infection, the number of simultaneous events and the type of first hepatic decompensation, CDC stage, nadir CD4 and CD4 cell counts at the first decompensation, plasma HIV viral load, HAART at the moment of decompensation, exposure to HAART during the follow-up, number of visits with undetectable plasma HIV-RNA viral load during the follow-up and exposure to specific antiretroviral drugs during the study period. The prescription of HAART was analysed in an intention-to-treat approach. The variables were entered into a Cox regression model if a difference with a P < 0.2 in the univariate analysis was found. The respective hazard ratios (HR) with 95% confidence intervals (CI) were obtained. Child-Pugh and MELD scores were treated as continuous in this analysis.
The statistical analysis was carried out using the SPSS 11 statistical software package (SPSS Inc., Chicago, Illinois, USA).
Ethical aspects
This study was designed and performed according to the Helsinki declaration. The ethics committee of each participant hospital approved the protocol.
Results
Features of the study population One hundred and fifty-three patients fulfilled the inclusion criteria of the study. The characteristics of the population at the time of the first hepatic decompensation are summarized in Table 1 . Liver cirrhosis was diagnosed by liver biopsy in 25 (16%) subjects. Eighty-nine (58%) patients were receiving HAART at the first hepatic decompensation. However, only 33 (38%) of them showed plasma HIV-RNA concentrations below 50 copies/ml. Eighty-six (56%) patients presented only one type of event at the first episode of decompensation, whereas 40 (26%), 22 (15%) and five (3%) subjects showed two, three or four simultaneous events at admission, respectively. Ascites was the most common diagnosis at the first admission and was present in 100 (65%) patients. In four cases ascites was complicated with SBP. Forty-four (28%) individuals showed HE during the first hepatic decompensation. In 22 (14%) cases, non-obstructive jaundice was the event that led the patient to the hospital. Finally, six (4%) and four (2%) subjects presented with PHGB and HCC, respectively.
One hundred and one (66%) patients were prescribed HAART after the first episode of hepatic decompensation, but only 63 (41%) of them achieved undetectable plasma HIV viral load during the follow-up. The antiretroviral drugs and the combination regimens most frequently prescribed during the study period are summarized in Table 2 . Fifteen (10%) patients were active intravenous drug users during the follow-up.
Survival and causes of death
The median survival time of the study population was 13 (IQR, 3-53) months. The cumulative probability of survival at 1, 3 and 5 years were 50, 30 and 26%, respectively.
The life status could not be determined in seven (5%) individuals. Neither the life status nor the cause of death could be determined using clinical records in only two (1%) individuals. Ninety-five (62%) patients died during the follow-up. In 79 (85%) individuals, the cause of death was liver-related. Specifically, HE was the leading cause of mortality, accounting for 46 (49%) of deaths whereas SBP was the cause of death in 10 (11%) patients. PHGB, hepatorenal syndrome, acute liver failure and HCC were the causes of death in eight (8%), eight (8%), four (4%) and three (3%) subjects, respectively. AIDS only accounted for three (3%) of deaths. In 13 (14%) patients the cause of death was neither due to liver disease nor to AIDS.
Factors associated with survival
The factors that predicted survival in the univariate analysis were alanine-aminotransferase levels, ChildPugh stage, MELD score, the type of first hepatic decompensation, the number of simultaneous hepatic events, CDC stage, nadir CD4 cells and CD4 cell counts at first decompensation, taking HAART at the time of decompensation, plasma HIV viral load at first decompensation and showing undetectable plasma HIV viral load at least in one visit during the follow-up (Table 3 , Fig. 1a, b and c) .
Survival was significantly longer in patients who were prescribed HAART (Table 3 and Fig. 1d ). The cumulative probability of survival in patients under HAART was 60% at 1 year and 40% at 3 years, versus 38 and 18%, respectively, in patients without HAART (P < 0.0001).
Plasma HCV viral load was available in 54 patients. The median survival was shorter in patients harbouring plasma levels above 6.04 IU/ml (17 versus 48 months, P < 0.08). Age, sex, daily alcohol intake, active intravenous drug use during the follow-up, hepatitis B or D virus co-infection, the route and the length of HCV infection and HCV genotype were not associated with survival.
After multivariate analysis, the factors that independently predicted survival were a poorer Child-Pugh score, the 
D4T, stavudine; DDI, didanosine; PI, protease inhibitor; ZDV, zidovudine; 3TC, lamivudine; ABC, abacavir; EFV, efavirenz; LPV, lopinavir; RTV, ritonavir; TDF, tenofovir.
presence of HE at the first decompensation, CD4 cell counts lower than 100 cells/ml at the time of first hepatic decompensation and the prescription of HAART along the follow-up (Table 3 ).
The impact of the specific antiretroviral drugs on survival was assessed in the subgroup of 101 patients exposed to ART during the follow-up. Patients with PI-based regimens showed similar survival to that found in individuals with efavirenz including HAART (30 versus 33 months, P ¼ 0.9). The effect of nevirapine on survival could not be evaluated, as it was prescribed only in six patients after the first decompensation. No impact of specific drugs on the survival was observed.
Univariate and multivariate analyses using liver-related mortality as the outcome variable instead overall mortality yielded similar results (Fig. 1d ).
Discussion
This study shows that the survival of HIV-infected patients harbouring HCV-related ESLD is extremely poor, with roughly half of the patients dying within 1 year following the first hepatic decompensation. Predictors of survival in this population are the markers of severe liver disease, such as Child-Pugh score or HE. Moreover, the Survival in HIV-infected patients with HCV-related ELSD Merchante et al. 53 Table 3 . Predictors of overall mortality after the first hepatic decompensation. degree of immunosuppression, as measured by the CD4 cell count at the time of the first hepatic decompensation, was another strong predictor of liver-related mortality. In agreement with that, HAART seems to reduce the mortality due to ESLD.
Independent factors associated with liver mortality in the present study were some markers of liver disease severity, such as Child-Pugh score and HE. It is well known that HE has a negative impact on the survival of cirrhotic subjects [12, 13] , including those with HCV-related cirrhosis [6, 14] . Moreover, the frequency of HE as both the first event and the cause of death was higher in HIVco-infected patients in a previous retrospective survey, in which some of the patients analyzed here were also included [6] . According to this, HE was the leading cause of mortality among HIV/HCV-co-infected patients with ESLD in the present study. The reasons for this increased incidence of HE in the HIV-co-infected population are unclear. Consumption of depressors of central nervous system, which is frequent among HIV-infected individuals, or a higher frequency of bacterial infections could explain these differences. However, whether these topics contribute to the development of HE more frequently in the HIV-co-infected population needs to be elucidated.
As stated above, Child-Pugh score was another independent predictor of survival in the present study. Surprisingly, MELD score was not associated with survival after the multivariate analysis. Although MELD score is a good predictor of mortality in patients with chronic liver disease [15] , its prognostic worth in HIVinfected patients with ESLD has not been evaluated. According to our results, the Child-Pugh score has a higher prognostic value than MELD score to predict mortality in HIV-infected patients with decompensated cirrhosis when considered together. These differences are probably due to the fact that MELD score does not include the presence of HE, a frequent adverse clinical outcome with an ominous significance in this population.
The present study has a few limitations. Although the study cohort was prospectively designed and followed-up to assess mortality, there were no fixed ART interventions in the patients who developed ESLD. Thus, the analysis of the impact of HAART on liver-related mortality was performed retrospectively. For this reason, potential bias due to lack of homogeneity in patients management can not be excluded, as HAART could be more frequently prescribed to patients with a better clinical situation or those more compliant with the follow-up schedule. Due to this, the results of this study concerning the effect of HAART on liver-related mortality in HIV/HCV-coinfected patients with ESLD should be interpreted cautiously. However, the convergence of results showing benefits of HAART in reducing the liver-related mortality in such a population [7, 8] suggest that the data reported here reflect the clinical reality. Furthermore, the effect of HAART on survival was independent of the CD4 cell count in the multivariate analyses, which suggest that this bias should not have been important. On the other hand, many physicians prescribed HAART to the patients of this cohort. Prescriptions were free, provided that they complied with the most commonly used guidelines, mainly the Department of Health and Human Services (DHHS) guidelines. This fact resulted in a wide variety of regimens, which prevented the analysis of the relationship between specific drugs or combinations and survival. Only a prospective study with randomized allocation of patients to HAART and control groups would avoid these problems. This kind of study would be ethically acceptable only in patients with asymptomatic HIV infection and high CD4 cell count, which is a bias itself, along with the fact that it would take years until an answer is given. Since survival of HIV/ HCV-co-infected patients after the first hepatic decompensation is short, this answer is urgently needed.
This is the first work to our knowledge that has prospectively evaluated the survival of HIV/HCV-coinfected patients with ESLD. As stated above, the probability of survival was as low as 50% at 1 year after the first hepatic decompensation. This prognosis was dramatically worse in the absence of HAART. In this sense, less than 20% of patients who did not receive ART were alive after 3 years following the first hepatic decompensation in the present study. Due to this, therapy against HCV infection should be a priority. In fact, the combination of pegylated interferon plus ribavirin leads to a substantial rate of sustained virological responses or transient control of HCV viremia during therapy [16] . Both circumstances are associated with a reduced incidence of decompensated liver disease, HCC and liverrelated deaths [17] . Although HCV therapy should be given as early as possible, in order to prevent ESLD, it might be also worth giving it in patients with advanced liver disease [18] .
As stated above, the positive impact of HAART on the liver-related mortality of HIV/HCV-co-infected patients with ESLD found in the present study is in agreement with that found in previous surveys that have evaluated the effect of HAARTon the clinical course and outcome of HCV-related liver disease in HIV-infected subjects [7, 8] . However, they were retrospective studies based on HIV/HCV-co-infected populations irrespective of the stage of liver disease. For this reason, the specific effect of HAART in ESLD was not analysed in these studies. Moreover, in the Bonn cohort, 81% of the individuals were haemophiliacs [7] . This extreme does not represent the typical picture of the HIV/HCVco-infected populations, mainly in terms of treatment adherence.
The favourable effect of HAARTwas independent in our study of a marker of good control of HIV disease, such as achieving an undetectable plasma HIV viral load. This suggests that ART itself, rather than its virological consequences, delays the evolution of liver disease. This figure may be explained on the basis of the immune reconstitution associated with HAART. In fact, immunosupression has been associated with the evolution of chronic hepatitis C in the setting of HIV co-infection, as low CD4 cell count correlates with faster fibrosis progression [1, 19, 20] . In this regard, CD4 cell count lower than 100cells/ml at the first hepatic decompensation were associated with increased liver-related mortality in the present work. HAART induces promptly immune system recovery, even in the absence of complete virological response [21] . Consequently, HAART-associated immune restoration could positively influence the evolution of liver disease via CD4 cell recovery, regardless of whether complete virological control is achieved.
Liver transplantation has recently become a proper treatment option in HIV-infected patients with HCVrelated ESLD [9, 10] . However, the protocols currently used to include HIV-infected patients in liver transplantation programmes consider the same hepatic criteria as those for the general population [9, 22] , as these criteria are based on survival studies conducted in HIVuninfected patients. As survival of HIV-infected patients with decompensated cirrhosis is extremely short, specific protocols for this population aimed to identify high-risk patients are needed. According to our results, low CD4 cell count, Child score and the presence of HE are factors that must be taken into account to decide the appropriate transplantation timing.
In summary, this study demonstrates that survival of HIV/ HCV-co-infected patients with decompensated cirrhosis is very poor. Immunosuppression seems to play a key role in the outcome of liver disease. In contrast, HAART reduces liver-related mortality in this setting. If these data are confirmed, HAART should be strongly recommended in these patients. Although no specific recommendations can be made only on the basis of this study, HAART probably should be started earlier in HIV/ HCV-co-infected patients than in the HIV-monoinfected population. In fact, preventing advanced immunosuppression may have an important impact in avoiding liver disease progression.
